Results 231 to 240 of about 81,731 (287)
Heterogeneous‐catalyzed selective and versatile hydrogenative functionalizations of phthalimides have been developed for the first time. By using a solid nanocomposite formed by [Ag/Al2O3] material in combination with [H‐BETA] zeolite as cocatalyst, a broad range of 3‐functionalized isoindolinones have been accesed in one‐pot from phthalimides, H2 and ...
Carles Lluna‐Galán +2 more
wiley +1 more source
Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley +1 more source
The study shows that noncardiac surgical inflammation rapidly disrupts HDL function and cholesterol efflux in mice and human patients. Impaired reverse cholesterol transport after surgery drives rapid lipid accumulation, NETosis, and apoptosis within atherosclerotic plaques.
Dominique M. Boucher +15 more
wiley +1 more source
The Role of Ionic Liquids at the Biological Interfaces in Bioelectronics
Ionic liquids (ILs) are highlighted as key artificial ionic materials that bridge biological ion‐based signaling and electronic devices. By understanding their composition, structure, function relationships, and mechanisms, ILs can advance from high performance electrolyte to core materials enabling integrated, multifunctional bioelectronics for ...
Yeong‐sinn Ye +5 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Bulletin du cancer, 2011
With the approval of mechlorethamine by the FDA in 1949 for the treatment of hematologic malignancies, alkylating agents are the oldest class of anticancer agents. Even though their clinical use is far beyond the use of new targeted therapies, they still occupy a major place in specific indications and sometimes represent the unique option for the ...
Victor A. Filadora, Mark J. Lema
+5 more sources
With the approval of mechlorethamine by the FDA in 1949 for the treatment of hematologic malignancies, alkylating agents are the oldest class of anticancer agents. Even though their clinical use is far beyond the use of new targeted therapies, they still occupy a major place in specific indications and sometimes represent the unique option for the ...
Victor A. Filadora, Mark J. Lema
+5 more sources
1989
The phenotypic expression of intrinsic or natural resistance and the selection of acquired resistance through sublethal exposure to anticancer agents remain major obstacles to the successful treatment of human neoplasms. A large number of solid tumors that fail to respond to chemotherapy do so because they possess characteristics that allow them to ...
M L, Clapper, K D, Tew
openaire +2 more sources
The phenotypic expression of intrinsic or natural resistance and the selection of acquired resistance through sublethal exposure to anticancer agents remain major obstacles to the successful treatment of human neoplasms. A large number of solid tumors that fail to respond to chemotherapy do so because they possess characteristics that allow them to ...
M L, Clapper, K D, Tew
openaire +2 more sources

